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ABSTRACT 
 
Background and objectives  
The infant’s immune system evolves over the first months and years of life.  Strong positive 
correlation exists between lymphocyte count, lymphocyte subpopulations and gestational age 
at birth.  Associations with antenatal and postnatal steroid treatment, infection and chronic 
lung disease have also been described.  Few published studies report the effect of increasing 
postnatal age (PNA) and comorbidities on lymphocyte subpopulations in premature infants 
beyond the first 4 months of life.   This study aimed to describe changes in lymphocyte 
subpopulations in preterm infants up to 13 months PNA. 
 
Methods 
Premature infants (23-34 weeks completed gestation) from 5 centres had lymphocyte 
subpopulations measured at 2, 5 or 7, 12 and 13 months PNA alongside their vaccine 
responses in a vaccination trial. 
 
Results 
393 blood samples from 151 b bies were analysed.  There was an increase in absolute 
numbers of total lymphocytes (median cell count 6.21 x10
9
/L at 13 months compared with 
4.9 x10
9
/L at 2 months PNA) and CD3
+
, CD4
+
, CD8
+
, natural killer and B cells with 
increasing age.  At 2 months PNA there was a positive correlation between gestation and 
CD3
+ 
and CD4
+ 
counts (r=0.32 and 0.46 respectively) and proportions (r=0.22 and 0.41 
respectively), and CD4
+
:CD8
+
 ratios (r=0.57) but a negative correlation with CD8
+
 
proportions (r=-0.32).   
 
Conclusions  
This longitudinal study describes the distribution of lymphocyte subpopulations in premature 
infants and provides reference ranges for the major lymphocyte subsets to help guide 
clinicians when assessing premature infants for immunodeficiency in the first year of life. 
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INTRODUCTION 
Infection is a leading cause of morbidity and mortality in young infants and especially 
in those born prematurely [1–3].  Lymphocytes are key to the development of adaptive 
immunity and there are major changes in their numbers and function in term infants 
over the first year of life [4,5].  Reference ranges for lymphocyte counts and 
subpopulations exist for term infants and describe an increase in absolute counts in most 
lymphocyte subsets over the first 6 months of life [6,7]. 
Several studies have explored the effect of gestational age on lymphocyte 
subpopulations at birth [8–17].  Overall these studies show increasing concentrations of 
CD3
+
, CD4
+
, natural killer (NK) and B cells with increasing gestation.   
Factors other than gestational age may affect lymphocyte subset populations. The use of 
antenatal steroids, for example, has been associated with increased cord blood T cells 
together with diminished T cell proliferation [11,13,18,19].   
Few studies have described the changes in lymphocyte subpopulations after birth in 
premature infants who may have several months of ex-utero life before reaching term 
equivalent.  Lymphocytes in these babies are likely to be influenced by both the infants’ 
in-utero condition and their subsequent postnatal course.   Existing studies have 
included only a small numbers of babies and have limited the follo -up period to the 
first 6 months of life [17,20–22], thus the ‘normal’ subpopulation values in ex-
premature infants are unknown [23].  
This study aimed to describe the lymphocyte subpopulations in premature infants over 
the first 13 months of postnatal life and to determine the impact of antenatal and 
postnatal exposures and comorbidities.   
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MATERIALS AND METHODS  
This was a planned sub-study of a vaccination trial in which premature infants received 
the UK primary immunisation schedule and were randomised to 3 different schedules of 
the 13-valent pneumococcal conjugate vaccine (PCV13) (supplementary table 1).  It 
included all infants enrolled at 5 of the 12 vaccination study sites.  The clinical teams 
identified potentially eligible infants and parents were provided with information by the 
research teams.  Infants were eligible for inclusion if they were born before 35
+0
 weeks 
gestation, were medically fit for vaccination as defined by UK Department of Health 
guidelines [24] and were between 7 and 12 weeks PNA at the first vaccination dose.   
The study was approved by the East of England - Essex regional ethics committee (REC 
reference 07/HO301.11) and written informed consent was obtained from the infants’ 
parents or legal guardians prior to recruitment.  The clinical trial was registered 
(EudraCT number 2007-007535-23). 
Blood sampling and laboratory methods 
Each infant had up to 4 blood samples obtained: at 2 months of age, at 5 or 7 months of 
age (1 month after their final primary vaccinations) and prior to and 1 month after their 
booster vaccinations at 12 months of age (supplementary table 1).  Whole blood (1-2 
mL) was collected by venepuncture or capillary sampling into EDTA bottles for 
lymphocyte subpopulation quantification. All participants were well at the time of 
phlebotomy with no active infection as assessed by the clinical team.  Due to the 
challenges of obtaining sufficient blood volumes from premature infants, not all babies 
had samples collected at every time point and, due to the design of the study, fewer 
infants had blood sampling at 7 months of age than at 5 months of age. 
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Blood samples for lymphocyte analysis were processed within 12 hours of collection in 
the local NHS laboratory and analysed using their routine flow cytometry practice (as 
advised by the manufacturer and local standard operating procedures, table 1).   
 
Cell populations measured are shown in supplementary table 2 and supplementary 
figure 1 [22].  Whilst all centres enumerated CD3
+
, CD3
+
CD4
+
 and CD3
+
CD8
+ 
cells, 
due to local constraints different markers were used for detection of B cells and NK 
cells.  For B cells, 4 centres measured CD19
+
 and one CD20
+
 cells, whilst for NK cells 
4 centres measured CD56
+
 and one CD56
+
CD16
+
 cells.  For the purpose of overall 
trends these have been combined into ‘B cells’ and ‘NK cells’.   
 
Statistical analysis 
Due to the design of the main vaccination trial there was considerable overlap of ages at 
the final 2 blood samples.  Therefore for the purposes of this sub-study, the 12 and 13 
month samples were categorised according to age, rather than their relationship to 
vaccination.  A result was considered a ‘12 month’ sample if it was taken between 353 
and 387 days of age, and a “13 month” sample if taken after 387 days of age.  If 
participants had more than one sample within each age category only the first was 
included. 
The data were not all normally distributed and nonparametric tests of statistical 
significance were used.  Correlations were calculated using Spearman’s rank correlation 
coefficient.  For regression analysis loge transformed values were used.  For B cells and 
NK cell regression analysis, as different cell populations were measured, CD19
+
 and 
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CD56
+
 were analysed due to the smaller number of CD20
+
 and CD56
+
CD16
+
 results 
(368 and 366 results compared with 49 and 46 results respectively). 
To assess associations between subpopulations, clinical conditions and comorbidities 
univariable regression analysis was performed on the 2 month and 5 month results for 
the following variables: sex, small for gestational age (SGA, defined as birth weight less 
than the 10
th
 centile for gestation), chronic lung disease (CLD, defined as requiring 
supplemental oxygen or respiratory support at 28 days of age) and receipt of antenatal 
steroids.  All analyses were adjusted for gestation and study centre.  Backwards 
stepwise multivariable regression was performed for variables with significance in 
univariable analysis (p≤0.2). 
All data were analysed using STATA version 13 (Stata Inc). 
 
RESULTS 
A total of 419 analysable samples were collected from 151 infants.  The number of 
infants contributing 1, 2, 3 or 4 samples was 25, 34, 42 and 50 infants respectively.  26 
samples were excluded as they were the second sample collected between 353 and 387 
days of age.  The characteristics of the infants are shown in table 2.  
 
Effect of gestational and postnatal age 
The lymphocyte subpopulation results for different gestational and postnatal ages are 
shown in table 3, table 4 and figure 1.  Overall, there was an increase in the total 
lymphocyte count and all measured cell populations over the first 13 months of life.  
There was an increase in the percentage of CD3
+
CD8
+
 and NK cells and a decrease in 
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the percentage of CD3
+
CD4
+
 cells with increasing age.  The CD4
+
:CD8
+
 ratio 
correlated negatively with age.   
At 2 months of age there was a positive correlation between gestation and CD3
+
 count 
and percentage (r=0.32 and 0.22, p=0.001 and 0.028 respectively), CD3
+
CD4
+
 count 
and percentage (r=0.46 and 0.41 respectively, p<0.001 for both), and a negative 
correlation with the proportion of CD3
+
CD8
+
 cells (r=-0.32, p=0.001), resulting in 
positive correlation between CD4:CD8 ratio and birth gestation (r=0.57, p<0.001).  
The impact of gestation was rarely significant (p<0.05) after 2 months of age.  The only 
significant associations were the proportion of B cells at 7 months (r=-0.41, p=0.022), 
NK proportions at 12 months (r=0.22, p=0.023) and CD3
+
CD8
+
 and B cell proportions 
at 13 months (r=-0.29 and 0.28, p=0.011 and 0.014 respectively). 
 
There were no differences between infant lymphocyte profiles according to 
randomisation group (data not shown). 
 
Associations between co-morbidities, chronic lung disease, antenatal steroids, and 
lymphocyte subpopulations 
There were negative associations between CLD and CD3
+
 count (fold effect – FE -0.78  
i.e. 22% reduction in CD3
+
 count if CLD present, 95% CI 0.65-0.94; p=0.011), 
CD3
+
CD4
+
 count (FE 0.78, 95% CI 0.64-0.95; p=0.016) and CD19
+
 count (FE 0.72, 
95% CI 0.53-0.98; p=0.037) and between receipt of antenatal steroids and CD3
+
CD4
+
 
percentage (FE 0.86, 95% CI 0.74-1.00, p=0.047) at 2 months PNA only.  Postnatal 
steroids were rarely administered to infants (4 participants).   There was no association 
between SGA and any lymphocyte subpopulation. 
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In multivariable regression the association between CD3
+
CD4
+
 percentage and 
antenatal steroids was no longer apparent.  Univariable regression revealed no 
significant associations at 5 months of age. 
 
Effect of study centre 
Centres 1 and 5 had significantly different results from the other centres for the 
following subpopulations: CD3
+
%, CD3
+
CD4
+
% (5 only), CD3
+
CD8
+
% and 
CD3
+
CD8
+
 count (1 only) and CD19
+
% (5 only).  In addition, there were significant 
differences between centre 4 and the other centres for CD56
+
% and CD56
+
 count.  
These differences remained despite adjustment for the different gestational age 
distributions at each centre.  
 
DISCUSSION  
To our knowledge, this is the largest study of lymphocyte subpopulations in premature 
infants reported to date and provides data up to 13 months of age which may assist 
clinicians in assessing the immune status of infants who were born prematurely. With 
increasing age (either gestational or postnatal), an increase in the numbers of 
lymphocytes in all subpopulations was observed.  The degree of increase varied 
between subpopulations, resulting in an overall increase in cytotoxic T cells and NK 
cells as a proportion of the total count and a decrease in the proportion of T helper cells 
over the first year of life.   
Several studies have reported changes in lymphocyte subpopulations over the first year 
of life in term infants.  Comparison with these studies is limited by their broad age 
categories and a focus towards comparison with adult values [4,25,26].  However, the 
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pattern of changes seen in the preterm infants studied are in keeping with those 
described in term infants [5–8].  However, whilst our data show an increase in NK cells 
over the first year of life, the converse is described in term infants [6,27].  The reason 
for this difference is not clear, but it is worth noting that within our dataset a significant 
rise in NK cells appears to occur after 12 months of age, influencing the overall trend. 
 
The effect of gestation on subpopulations was most apparent at the earliest samples 
when many of the i fants had not yet reached term-equivalent. This is consistent with 
the differences reported between premature and term infants at birth [8,9,13,16]
 
as well 
as in previous preterm infant longitudinal studies [20,22].  Berrington et al. reported 
lower total lymphocyte count, T cells, B cells and T helper cells at 2 months of age in 
18 preterm infants compared with term infants; some of these populations (total 
lymphocytes, T cells and T helper cells) remained significantly lower at their final 
sample at 6 months of age [22].  Walker et al. demonstrated positive correlations 
between cell count and gestation for all subpopulations up to 12 weeks of age; however, 
possibly due to the small numbers of participants (25 preterm infants), these results did 
not reach statistical significance[20].  
 
We found no consistent effect of gestation on the number or proportion of B cells at any 
time point.  Berrington et al. did report lower B cell counts in premature infants at 2 
months of age, which had resolved by 6 months of age but, similar to our data, Walker 
et al. found similar B cell counts across all gestations [20,22].   
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Although the absolute numbers of lymphocytes vary significantly with age, the relative 
proportions of the lymphocyte subsets remain more constant and will thus provide a 
simpler reference for clinicians. It is important for a reference range to be applicable to 
the whole population; it should be noted that the infants in our study were clinically 
well at the time of sampling but a significant proportion had a number of co-morbidities 
that are commonly associated with prematurity. In addition, the multicentre approach 
permits results to be more generalisable.   
 
Chronic lung disease was associated with lower CD3
+
, CD3
+
CD4
+ 
and CD19
+
 counts.  
A previous study found decreased CD2
+
 and CD3
+
CD4
+
 counts in premature infants 
with CLD at 3 weeks of age and Pelkonen et al. described similar findings in the 
lymphocyte subpopulations of ex-premature school children which were associated with 
CLD [17,28].  It may be that CLD per se, or an aspect of its treatment, may result in 
these immunological findings. An intriguing alternative hypothesis is that these 
abnormalities of immune function are present before the onset of CLD, predisposing to 
its development and to the recurrent respiratory infections that such infants are prone to 
[29].  As infants were first sampled after the diagnosis of CLD had been made it is not 
possible to ascertain if these abnormalities were present earlier. 
Unlike other studies, we did not find any association between antenatal steroids and 
lymphocyte subpopulations in our cohort.  Previous studies analysed cord blood 
samples and it may be that any significant effect of antenatal steroids had resolved by 2 
months of age [8,13].   
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LIMITATIONS 
Our study has some potential limitations.  It was conducted as a sub-study and, as such, 
there was no opportunity for pre-selecting different blood sampling time-points.  Early 
neonatal blood samples would have allowed a more complete description of the 
subpopulations from birth to one year of age.   Fortunately there is a pre-existing 
evidence base for cord blood of preterm infants at various gestational ages [8–13].   
The constraints of NHS laboratories also meant that the investigation of more refined 
subpopulations e.g. regulatory T and B cells, and functional studies were not possible.  
 
Additionally, laboratory analysis was performed within the routine clinical framework 
using different sample preparation and analysis techniques.  Accordingly, differences 
were found between the centres for nearly all subpopulations despite some centres using 
similar analytical laboratory protocols.  Correcting for other possible centre-dependant 
factors (e.g. gestation) using multiple regression did not eliminate these differences.  It 
is known that a variety of factors can affect the inter-laboratory quantification of 
absolute lymphocyte subpopulations [30–32] and other multicentre studies have 
experienced similar inter-centre variation, with testing centre the most significant factor 
in analysis of differences between cell populations [6].  Studies have negated this 
challenge by freezing peripheral blood mononuclear cells (PBMCs) and centralising 
samples prior to analysis; or performing single centre studies on whole blood [5,22].  
Unfortunately the volume of blood required to extract PBMCs is prohibitively large in 
low weight infants.  In order to address the inter-centre variation, the testing centre was 
included within the regression analysis. These factors should be considered when 
designing future studies. 
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Families were approached to take part in the study before 3 months of age.  Babies that 
were too unstable to be vaccinated at this time were unable to participate. This may 
have reduced the number of patients with complex clinical courses. To minimise this, 
recruitment was stratified by age group to ensure extremely premature infants were 
appropriately represented. 
 
Finally, this study did not include any term infants and as such direct comparison with 
them is not possible.   
 
CONCLUSION 
This is the largest reported cohort to describe lymphocyte subpopulations in premature 
infants and its longitudinal nature provides reference ranges for the major lymphocyte 
subsets. The effect of gestation on subpopulations is most pronounced in early life (up 
to approximately 6 months postnatal age), corresponding with when infants are most 
vulnerable to infection. This may be compounded in infants with co-morbidities, 
especially chronic lung disease, and further study is required to determine the nature of 
this relationship.   
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What is already known on this topic: 
 
• At birth, younger gestation is associated with lower concentrations of CD3
+
, 
CD4
+
, natural killer (NK) and B cells and increased CD4
+
:CD8
+
 ratios  
• Existing reference ranges describe major changes in lymphocyte subpopulation 
numbers in term infants over the first year of life  
• Limited information is available on the normal range of lymphocyte 
subpopulations in preterm infants after the first few months of life 
 
What this study adds: 
 
• Provides reference ranges for lymphocyte subpopulations in premature infants 
up to 1 year of age 
• Total lymphocyte, CD3
+
, CD4
+
, CD8
+
, B and NK cell counts increase up to 1 
year of age but subpopulation proportions are more stable 
• The effect of gestation is largest at 2 months of age and chronic lung disease is 
associated with a reduction in CD3
+
, CD4
+
 and CD19
+
 cells 
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Table 1: Flowcytometer methodology by centre.  
BC: Beckman Coulter Inc, Miami, USA; BD: Becton Dickinson Inc, San Jose, USA; 
Siemens AG Erlangen, Germany. FITC: Fluorescein isothiocyanate, PerCP-Cy5.5: peridinin 
chlorophyll protein cyanin 5.5, APC: allophycocyanin, PE: phycoerythrin.  
 
Table 2: Participant characteristics by gestational age at birth.  
Median (range) or n (%).   
a
Significant difference between groups (p<0.05). 
 
Table 3: Lymphocyte subpopulations by postnatal and gestational age at birth.   
Absolute count x10
9
/L.  Median (5-95th centile).  Lymphocytes: CD45
+
.  B cells: CD19
+
, 
CD20
+
.  NK cells: CD56
+
, CD56
+
CD16
+
.  p value calculated using Spearman rank correlation 
coefficient for postnatal age. 
 
Table 4:  Lymphocyte subpopulations by postnatal and gestational age at birth.  Percentage of 
total lymphocyte count.  Median % (5-95th centile). Lymphocytes: CD45
+
.  B cells: CD19
+
, 
CD20
+
.  NK cells: CD56
+
, CD56
+
CD16
+
.  p value calculated using Spearman rank correlation 
coefficient for postnatal age. 
 
Figure 1: Lymphocyte subpopulations at different gestational and postnatal ages (median 
percentage). A: Birth gestation <28 weeks, B: Birth gestation 28
+0
-31
+6
 weeks, C: Birth 
gestation: 32
+0
 – 34
+6
 weeks 
 
 
Table 1 
Centre Sample preparation Analyser 
Analysis 
Software 
Lymphocyte 
count 
1 BD FACS lyse 
BD individual monoclonal antibody 
reagent  
BD 
FACScalibur 
MultiSET Siemens 
Advia 2120 
2 BD multitest 6-colour TBNK reagent 
(CD3+ FITC / CD16+ & CD56+ PE / 
CD4
+
5 PerCP-C
TM
5.5 / CD4
+
 PE-
Cy
TM
7 / CD19 / CD8
+
 APC-Cy7) 
With BD Trucount tubes 
BD 
FACScanto 
II 
BD 
FACScanto 
v2.4 
Sysmex 
XE2100 
3 BC CYTO-STAT tetraCHROME 
reagent (CD4+5-FITC/CD4+-
RDI/CD8
+
-ECD/CD3
+
-PC5)  
BC FC500 TetraCXP  BC  LH750 
4 BC CYTO-STAT tetraCHROME 
reagent (CD4
+
5-FITC/CD4
+
-
RDI/CD8
+
-ECD/CD3
+
-PC5) 
BC FC500 TetraCXP BC DxH 
5 BD multitest 
CD3+/CD8+/CD4+5/CD4+  
BD multitest 
CD3
+
/CD16
+
CD56
+
/CD4
+
5/CD19
+
  
With BD Trucount tubes 
BD 
FACScanto 
II 
BD 
FACScanto 
v2.4 
NA (single 
platform) 
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Table 2 
 
 <28 weeks 28-31+6 weeks 32+0-34+6 weeks 
N 32 64 55 
Gestation (weeks) 26.5 (23.3-27.9) 29.7 (28-31.6) 33.4 (32-34.9) 
Birth weight (g)
a
 840 (490-1398) 1298 (521-2070) 1895 (1335-2680) 
Sex – male  19 (59) 27 (42) 29 (53) 
SGA 10 (31) 13 (20) 10 (18) 
CLD* 31 (97) 21 (33) 1 (2) 
Antenatal steroids 30 (94) 53 (83) 44 (80) 
Weight at first blood
a
 1900 (1070-2764) 2280 (845-3670) 3130 (2000-4620) 
Blood A samples (n) 24 48 33 
Blood A age (days)
a
 64 (54-83) 61 (48-84) 60 (49-86) 
Blood B samples – 5m  (n) 15 30 23 
Blood B age – 5m  (days) 159 (135-175) 158 (135-180) 149 (132-199) 
Blood B samples – 7m  (n) 11 11 16 
Blood B age – 7m  (days)
a
 207 (196-241) 206 (187-215) 195 (179-224) 
Blood C samples – 12m (n) 20 48 37 
Blood C age – 12m (days) 365 (353-387) 364 (354-385) 368 (353-387) 
Blood D samples – 13m (n) 17 36 24 
Blood D age – 13m (days) 399 (389-439) 401 (388-443) 407 (389-492) 
 
Table 3 
 
Population 
Gestation 
(weeks) 
2 months 5 months 7 months 12 months 13 months p 
Total 
Lymphocytes 
 
<28 
4.55  
(3.30-6.70) 
5.85  
(2.70-10.94) 
6.20  
(4.60-7.80) 
6.45  
(2.49-8.96) 
6.22  
(2.12-11.90) 
0.003 
28-31+6 
4.85  
(2.95-8.50) 
5.58  
(2.20-9.60) 
5.70  
(4.36-8.36) 
5.73  
(3.70-9.93) 
6.37  
(3.01-11.65) 
0.001 
32+0-34+6 
5.29  
(3.25-9.10) 
6.00  
(3.00-7.40) 
5.68  
(3.40-11.10) 
5.88  
(2.60-10.00) 
5.91  
(2.80-10.90) 
0.19 
All 
4.90  
(3.10-8.30) 
5.75  
(2.80-9.52) 
5.77  
(3.40-10.60) 
5.88  
(2.62-9.55) 
6.21  
(2.80-11.65) 
<0.001 
CD3
+
 
<28 
2.76  
(1.78-3.89) 
3.34  
(1.76-6.92) 
3.55  
(2.74-5.46) 
4.50  
(1.50-6.92) 
3.87  
(1.14-7.45) 
<0.001 
28-31+6 
3.13  
(1.90-4.81) 
3.45  
(1.22-6.90) 
3.66  
(2.81-5.92) 
3.75  
(1.88-7.27) 
4.30  
(1.89-6.58) 
<0.001 
32+0-34+6 
3.40  
(1.18-7.40) 
3.40  
(2.05-5.18) 
3.82  
(2.01-7.88) 
3.36  
(1.55-8.08) 
3.57  
(1.64-6.77) 
0.58 
All 
3.13  
(1.78-5.48) 
3.40  
(1.63-6.70) 
3.66  
(2.45-6.51) 
3.82  
(1.88-7.07) 
3.81  
(1.76-7.40) 
<0.001 
CD3
+
CD4
+
 
<28 
1.65  
(1.20-2.65) 
2.29  
(1.16-4.42) 
2.50  
(1.81-3.78) 
2.85  
(0.95-5.03) 
2.58  
(0.65-5.12) 
0.001 
28-31+6 
2.17  
(1.30-3.70) 
2.59  
(0.99-4.99) 
2.65  
(1.98-3.85) 
2.47  
(1.23-5.12) 
2.81  
(1.16-4.14) 
0.011 
32+0-34+6 
2.46  
(0.90-6.28) 
2.45  
(1.42-4.22) 
2.44  
(1.29-5.88) 
2.07  
(1.17-5.50) 
2.26  
(0.70-4.75) 
0.23 
All 
2.16 
(1.22-4.14) 
2.45  
(1.17-4.74) 
2.51  
(1.61-4.93) 
2.47  
(1.23-5.12) 
2.54  
(1.04-4.81) 
0.013 
CD3
+
CD8
+
 <28 
0.94  
(0.40-1.34) 
1.10  
(0.54-3.54) 
1.09  
(0.79-1.59) 
1.42  
(0.50-1.98) 
1.31  
(0.47-3.25) 
<0.001 
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28-31+6 
0.76  
(0.47-1.19) 
0.85  
(0.21-2.03) 
1.06  
(0.51-2.05) 
1.02  
(0.52-2.05) 
1.21  
(0.48-2.39) 
<0.001 
32+0-34+6 
0.88  
(0.28-1.71) 
0.76  
(0.36-1.38) 
1.01  
(0.36-2.05) 
1.09  
(0.28-2.41) 
0.83  
(0.53-2.24) 
0.021 
All 
0.84  
(0.44-1.33) 
0.86  
(0.34-1.85) 
1.04  
(0.51-2.05) 
1.09  
(0.45-2.07) 
1.19  
(0.48-2.50) 
<0.001 
B cells 
<28 
1.31  
(0.65-3.03) 
1.45  
(0.67-3.34) 
1.99  
(0.98-3.26) 
1.63  
(0.62-3.02) 
1.57  
(0.61-3.65) 
0.33 
28-31+6 
1.29  
(0.52-3.66) 
1.66  
(0.48-3.31) 
1.60  
(0.80-2.52) 
1.55  
(0.59-2.80) 
1.61  
(0.38-4.52) 
0.14 
32+0-34+6 
1.58  
(0.32-2.32) 
1.33  
(0.50-2.65) 
1.64  
(0.54-3.50) 
1.58  
(0.52-2.73) 
1.81  
(0.74-3.17) 
0.014 
All 
1.32  
(0.52-3.00) 
1.45  
(0.50-3.02) 
1.71  
(0.65-3.26) 
1.57 
(0.59-2.80) 
1.66  
(0.46-3.65) 
0.006 
NK cells 
<28 
0.26  
(0.04-0.59) 
0.27  
(0.02-0.66) 
0.30  
(0.05-1.47) 
0.22  
(0.10-1.42) 
0.46  
(0.09-1.31) 
0.008 
28-31+6 
0.23  
(0.06-0.60) 
0.23  
(0.04-1.42) 
0.23  
(0.05-0.66) 
0.28  
(0.08-0.75) 
0.38  
(0.12-1.57) 
0.001 
32+0-34+6 
0.25  
(0.04-0.82) 
0.22  
(0.06-0.50) 
0.26  
(0.03-1.65) 
0.35  
(0.08-1.16) 
0.41  
(0.13-1.51) 
<0.001 
All 
0.25  
(0.05-0.68) 
0.23  
(0.04-0.66) 
0.28  
(0.04-1.47) 
0.29  
(0.08-0.90) 
0.39  
(0.12-1.51) 
<0.001 
 
Table 4 
 
Population 
Gestation 
(weeks) 
2 months 5 months 7 months 12 months 13 months p 
CD3
+
 
<28  
59.0  
(38.0-79.0) 
65.0  
(52.0-77.0) 
60.4  
(47.0-73.0) 
67.4  
(45.0-79.5) 
63.7  
(50.0-80.0) 
0.04 
28-31+6 
64.1  
(47.0-82.0) 
65.0  
(42.0-86.3) 
62.0  
(59.0-70.8) 
67.0  
(51.0-80.6) 
65.2  
(46.1-89.0) 
0.42 
32+0-34+6 
65.5  
(53.0-86.0) 
66.4  
(46.0-81.0) 
67.5  
(42.0-79.0) 
63.0  
(52.0-78.0) 
60.0  
(46.0-71.0) 
0.026 
All 
64.0  
(45.0-82.0) 
65.0  
(46.0-83.0) 
62.1  
(47.0-74.0) 
65.0  
(52.0-80.0) 
63.1  
(46.1-82.0) 
0.86 
CD3
+
CD4
+
 
<28  
39.1  
(24.0-54.0) 
44.0  
(29.0-64.0) 
40.6  
(31.8-52.0) 
43.6  
(27.0-57.0) 
42.0  
(25.0-54.0) 
0.30 
28-31+6 
46.5  
(31.2-63.0) 
49.0  
(29.0-64.8) 
43.0  
(37.0-56.4) 
47.4  
(36.0-57.3) 
45.0  
(27.6-62.0) 
0.13 
32+0-34+6 
50.5  
(36.0-69.0) 
51.0  
(35.0-68.0) 
45.0  
(32.0-56.0) 
42.0  
(26.0-55.0) 
41.5  
(16.0-56.0) 
<0.001 
All 
46.0  
(26.0-63.0) 
49.0  
(33.0-67.0) 
43.0  
(32.0-56.0) 
44.0  
(32.0-57.0) 
43.0  
(21.0-56.2) 
0.002 
CD3
+
CD8
+
 
<28  
19.1  
(12.0-32.0) 
19.0  
(15.0-31.0) 
17.8  
(14.0-23.0) 
20.1  
(13.8-28.6) 
22.5  
(15.0-31.0) 
0.11 
28-31+6 
15.2  
(10.0-26.0) 
16.0  
(9.0-27.0) 
17.0  
(11.0-27.0) 
17.7  
(11.7-26.0) 
19.0  
(12.0-30.0) 
<0.001 
32+0-34+6 
15.8  
(10.0-22.0) 
15.5  
(9.0-25.0) 
17.5  
(7.5-31.0) 
18.0  
(11.0-28.0) 
17.0  
(12.0-28.0) 
0.032 
All 
16.0  
(10.0-26.0) 
16.0  
(9.0-26.0) 
17.4  
(11.0-30.0) 
18.0  
(12.0-28.0) 
19.0  
(12.0-31.0) 
<0.001 
B cells 
<28  
27.5  
(17.0-48.0) 
26.6  
(19.0-38.0) 
31.4  
(17.2-42.0) 
24.4  
(12.5-38.0) 
24.1  
(10.0-42.8) 
0.24 
28-31+6 
27.8  
(15.3-43.0) 
29.1  
(11.0-48.0) 
28.0  
(18.3-35.0) 
26.4  
(14.6-42.0) 
26.4  
(7.0-38.6) 
0.26 
32+0-34+6 
27.6  
(10.0-35.0) 
24.0  
(8.1-45.0) 
23.6  
(16.0-37.7) 
28.5  
(17.0-35.0) 
30.1  
(18.1-43.0) 
0.07 
All 27.8  27.0  27.8  26.9  27.2  0.84 
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(15.0-43.0) (11.0-45.0) (17.2-37.7) (15.0-39.5) (10.1-42.8) 
NK cells 
<28 
5.2  
(1.0-12.2) 
5.0  
(0.7-7.0) 
5.0  
(1.0-21.3) 
4.4  
(1.5-20.6) 
7.7  
(3.0-25.9) 
0.12 
28-31+6 
5.0  
(1.0-10.8) 
4.0  
(1.0-15.3) 
4.0  
(1.0-7.9) 
5.0  
(2.0-11.2) 
6.9  
(2.3-16.6) 
0.07 
32+0-34+6 
4.0  
(1.0-14.5) 
4.0  
(1.0-10.0) 
4.9  
(0.3-34.6) 
5.7  
(2.0-25.1) 
8.1  
(2.0-24.1) 
<0.001 
All 
0.25  
(0.05-0.68) 
0.23  
(0.04-0.66) 
0.28  
(0.04-1.47) 
0.3  
(0.1-0.9) 
0.4  
(0.1-1.5) 
0.001 
CD4
+
:CD8
+
 
<28 
1.93  
(1.27-2.85) 
2.23  
(0.96-4.02) 
2.36  
(1.69-3.00) 
2.07  
(1.37-3.49) 
2.1  
(0.8-3.0) 
0.68 
28-31+6 
3.00  
(1.54-5.07) 
3.38  
(1.76-5.22) 
2.61  
(1.52-4.84) 
2.60  
(1.51-4.14) 
2.5  
(1.3-3.9) 
<0.001 
32+0-34+6 
3.11  
(2.33-5.00) 
3.34  
(1.79-5.58) 
2.78  
(1.09-4.55) 
2.49  
(0.93-4.23) 
2.4  
(0.8-4.7) 
<0.001 
All 
2.77  
(1.54-4.90) 
3.05  
(1.76-5.57) 
2.53  
(1.27-4.57) 
2.46  
(1.40-4.14) 
2.35  
(0.79-4.05) 
<0.001 
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Figure 1: Lymphocyte subpopulations at different gestational and postnatal ages (median percentage). A: 
Birth gestation <28 weeks, B: Birth gestation 28+0-31+6 weeks, C: Birth gestation: 32+0 – 34+6 weeks  
254x184mm (300 x 300 DPI)  
 
 
Page 23 of 27
https://mc.manuscriptcentral.com/adc
Archives of Disease in Childhood
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplementary figures 
Supplementary table 1:  Study design.  Pediacel (Sanofi Pasteur MSD), Prevenar13 (Pfizer 
Inc), Menjugate (Novartis Diagnostics and Vaccine, Siena, Italy), Priorix (GlaxoSmithKline 
Ltd) and Menitorix (GlaxoSmithKline Ltd) 
 
 
Supp Table 1 
 
 
 
Approx. 
age 
(months) 
2 3 4 5 6 7 12 13 
Group 1   
Blood sample 
PediacelTM 
Prevenar13TM 
PediacelTM 
MenjugateTM 
PediacelTM 
MenjugateTM 
Prevenar13
TM
 
Blood 
sample 
 
  
Blood sample 
PriorixTM 
MenitorixTM 
Prevenar13
TM
 
Blood 
sample 
 
 
Group 2 
Blood sample 
PediacelTM 
Prevenar13TM 
PediacelTM 
MenjugateTM 
Prevenar13TM 
PediacelTM 
MenjugateTM 
Prevenar13
TM
 
Blood 
sample 
 
 
 
 
Blood sample 
PriorixTM 
MenitorixTM 
Prevenar13
TM
 
Blood 
sample 
 
Group 3 
Blood sample 
PediacelTM 
Prevenar13TM 
PediacelTM 
MenjugateTM 
 
PediacelTM 
MenjugateTM 
Prevenar13
TM
 
 
 
Prevenar13TM 
Blood 
sample 
 
Blood sample 
PriorixTM 
MenitorixTM 
Prevenar13
TM
 
Blood 
sample 
 
Page 24 of 27
https://mc.manuscriptcentral.com/adc
Archives of Disease in Childhood
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplementary table 2: Lymphocyte subpopulations measured 
Supp Table 2 
Cell population CD Marker 
Total lymphocyte count Side scatter and CD45 
T cell CD3 
T helper cell CD3/CD4 
Cytotoxic T cell CD3/CD8 
Natural killer cell CD56 and/or CD16 
B cell CD19 or CD20 
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Supplementary figure 1 
Lymphocytes selected (CD45 bright, low side scatter)  
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